Specific correction of impaired acid hydrolase secretion in storage pool-deficient platelets by adenosine diphosphate.
Storage pool-deficient (SPD) platelets, which have decreased amounts of dense-granule and/or alpha-granule constituents, contain normal amounts of lysosomal acid hydrolases, but in some cases exhibit impaired secretion of these enzymes. We examined this impaired secretion response in SPD patients with varying extents of granule deficiencies, and determined the effects of added dense-granule constituents. Acid hydrolase secretion was impaired in patients with severe dense-granule deficiencies, but not in patients with lesser dense-granule deficiencies, including those with alpha-granule deficiencies as well. When dense-granule constituents (ADP, ATP, serotonin, Ca+2, pyrophosphate) were added to gel-filtered platelets, ADP, but none of the other constituents, completely corrected the impairment of thrombin and A23187-induced secretion in SPD platelets. The concentration of ADP required to normalize thrombin-induced secretion varied markedly, from 0.01 to 10 microM, among the individual patients. Fixation of platelets with formaldehyde before centrifugation did not prevent the enhancement of secretion by ADP. Excess ATP, which acts as a specific antagonist of ADP-mediated responses, completely blocked this enhancement of secretion in SPD platelets by ADP, and partially inhibited acid hydrolase secretion induced by low, but not high, concentrations of thrombin in normal platelets as well. Treatment of normal platelets with acetylsalicylic acid in vivo, but not in vitro, produced an impairment of acid hydrolase secretion similar in extent to that in SPD platelets, but which could not be completely corrected by added ADP. One possible explanation of these results is that the impairment of acid hydrolase secretion may be secondary to the dense-granule deficiency in SPD platelets, and that secreted ADP may potentiate the lysosomal secretion response in normal platelets as well.
Lages
B
B
Department of Medicine, Columbia University College of Physicians and Surgeons, New York 10019.
Dangelmaier
C A
CA
Holmsen
H
H
Weiss
H J
HJ
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D001791:Blood Platelet Disorders / Q000201:enzymology*; D001792:Blood Platelets / Q000187:drug effects* / Q000201:enzymology; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D005557:Formaldehyde / Q000494:pharmacology; D006801:Humans; D006867:Hydrolases / Q000097:blood / Q000378:metabolism*; D010981:Platelet Storage Pool Deficiency / Q000201:enzymology*; D013917:Thrombin / Q000494:pharmacology; D001619:beta-N-Acetylhexosaminidases / Q000097:blood / Q000378:metabolism
D005557:Formaldehyde; D000001:Calcimycin; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D006867:Hydrolases; D001619:beta-N-Acetylhexosaminidases; D013917:Thrombin; D001241:Aspirin; D002118:Calcium; D004837:Epinephrine